ASX Release
ASX Code: MEM

20 August 2026

FELIX™ REGISTRATION ACHIEVED IN VIETNAM, TRIGGERING 600-CARTRIDGE ORDER

Highlights

- **Vietnamese registration for the Felix™ System has been achieved in August 2026, in line with the timetable previously advised to the market.**
- **Registration triggers TMSC Vietnam's first commercial order of 600 Felix™ cartridges under its two-year A$530,000 exclusive commercialisation agreement with Memphasys.**
- **The 600-cartridge order is in addition to 100 cartridges already delivered for in-market testing and clinical preparation, taking total cartridges delivered or ordered for Vietnam to 700.**
- **TMSC Vietnam has successfully commenced introducing Felix™ to fertility clinics and has reported the first successful pregnancy following use of the system by a client clinic in Vietnam.**
- **Regulatory clearance enables full commercial sales to commence in one of South-East Asia's fastest-growing assisted reproductive technology markets.**

Memphasys Limited (ASX: MEM) (Memphasys or the Company) is pleased to advise that registration of the Felix™ System in Vietnam has been achieved, completing the regulatory milestone within the August 2026 timeframe previously announced by the Company.

The registration allows full commercial sales of Felix™ to commence in Vietnam and triggers TMSC Viet Nam Medical Technology Company Limited's (TMSC Vietnam) first commercial order of 600 Felix™ cartridges. This order is in addition to the 100 cartridges and three consoles previously supplied to support in-market testing, product introduction and clinical preparation ahead of the full commercial launch.

TMSC Vietnam has also advised Memphasys that its early engagement with fertility clinics over the past 3 weeks has resulted in the first successful pregnancy reported following the use of Felix™ by a client clinic in Vietnam. While an individual clinical outcome does not establish or predict outcomes for other patients, the early result is an encouraging milestone as TMSC Vietnam moves from market preparation into broader commercial introduction.

Commercial rollout now underway

Memphasys entered into a two-year exclusive commercialisation agreement with TMSC Vietnam on 1 June 2026 for the sale and distribution of the Felix™ System in Vietnam. The agreement has a total contracted value of A$530,000, comprising A$205,000 in Year 1 and A$325,000 in Year 2, with contracted quarterly cartridge volumes increasing as clinical adoption develops.

The 600-cartridge order forms part of those contracted purchase commitments and, together with the 100 cartridges already delivered, takes the total number of Felix™ cartridges delivered or ordered for Vietnam to 700. The order represents the transition from pre-launch clinical preparation to full commercial supply.

Under the commercial model, Memphasys works alongside TMSC Vietnam on product education, clinical positioning and market development, while TMSC Vietnam uses its local regulatory expertise, reproductive-health experience and relationships across the Vietnamese healthcare system to build clinic adoption.

Memphasys Limited
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

Contact Details
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

Vietnam market opportunity

Vietnam is an important assisted reproductive technology market in South-East Asia, supported by increasing healthcare investment, rising demand for fertility services and expanding fertility infrastructure across Hanoi and Ho Chi Minh City.

TMSC Vietnam is a Hanoi-based medical technology company with an established focus on reproductive health, diagnostics, digital health tools and medical-device distribution. Its experience in male fertility and its existing relationships with Vietnamese healthcare providers make it well placed to support the national rollout of Felix™.

Outlook

With registration now complete, Memphasys and TMSC Vietnam will focus on converting early clinic engagement into broader adoption and recurring cartridge sales. The Company will continue to support training, product education and selected clinic engagement as the commercial rollout progresses.

The achievement of registration on schedule, commencement of the first 600-cartridge commercial order and first reported pregnancy following use of Felix™ demonstrate tangible progress against the Vietnam market-entry plan outlined in June 2026.

This announcement has been authorised for release by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby
Chapter One Advisors
T: +61 433 112 936
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted and recurring sales through direct and distribution-led channels, scaling production to support commercial growth, and establishing Felix™ as a new global standard in sperm preparation for assisted reproductive technology procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Memphasys' current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions. Words such as 'anticipates', 'expects', 'intends', 'plans', 'believes', 'seeks', 'estimates', 'guidance' and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties and are not guarantees of future performance. Memphasys cautions shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.